EA201992757A1 - Биспецифические антитела-ингибиторы контрольной точки - Google Patents

Биспецифические антитела-ингибиторы контрольной точки

Info

Publication number
EA201992757A1
EA201992757A1 EA201992757A EA201992757A EA201992757A1 EA 201992757 A1 EA201992757 A1 EA 201992757A1 EA 201992757 A EA201992757 A EA 201992757A EA 201992757 A EA201992757 A EA 201992757A EA 201992757 A1 EA201992757 A1 EA 201992757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
specific point
point inhibitors
human
inhibitors
cancer
Prior art date
Application number
EA201992757A
Other languages
English (en)
Inventor
Майкл Дивейн Кейлос
Ивэнь Ли
Дейл Линкольн Людвиг
Грегори Д. Плоуман
Ян Шэнь
Игор Эдмондо Паоло Д'Анджело
Original Assignee
Эли Лилли Энд Компани
Займворкс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани, Займворкс, Инк. filed Critical Эли Лилли Энд Компани
Publication of EA201992757A1 publication Critical patent/EA201992757A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Abstract

Данное изобретение относится к антителам, которые являются гетеродимерными и связывают PD-L1 человека и PD-1 человека, и могут быть полезны в лечении рака сами по себе и в комбинации с химиотерапией и другими противораковыми терапевтическими средствами.
EA201992757A 2017-07-10 2018-07-09 Биспецифические антитела-ингибиторы контрольной точки EA201992757A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530436P 2017-07-10 2017-07-10
PCT/US2018/041205 WO2019014091A1 (en) 2017-07-10 2018-07-09 BISPECIFIC ANTIBODIES AS INHIBITORS OF CONTROL POINTS

Publications (1)

Publication Number Publication Date
EA201992757A1 true EA201992757A1 (ru) 2020-04-27

Family

ID=63013165

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992757A EA201992757A1 (ru) 2017-07-10 2018-07-09 Биспецифические антитела-ингибиторы контрольной точки

Country Status (26)

Country Link
US (1) US11203640B2 (ru)
EP (1) EP3652216A1 (ru)
JP (1) JP6953612B2 (ru)
KR (1) KR102309950B1 (ru)
CN (1) CN110914306B (ru)
AR (1) AR112603A1 (ru)
AU (1) AU2018301326B2 (ru)
BR (1) BR112020000162A2 (ru)
CA (1) CA3069254C (ru)
CL (1) CL2020000053A1 (ru)
CO (1) CO2019015100A2 (ru)
CR (1) CR20190576A (ru)
EA (1) EA201992757A1 (ru)
IL (1) IL271347B2 (ru)
JO (1) JOP20200003B1 (ru)
MA (1) MA49563A (ru)
MX (1) MX2020000242A (ru)
MY (1) MY195071A (ru)
NZ (1) NZ760683A (ru)
PE (1) PE20200297A1 (ru)
PH (1) PH12020500075A1 (ru)
SG (1) SG11201911817VA (ru)
TW (1) TWI714864B (ru)
UA (1) UA126032C2 (ru)
WO (1) WO2019014091A1 (ru)
ZA (1) ZA201908549B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3035681A1 (en) 2016-09-29 2018-04-05 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3533804A4 (en) 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
JP2020512836A (ja) * 2017-04-01 2020-04-30 北京韓美薬品有限公司 抗ｐｄ−ｌ１／抗ｐｄ−１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
US11939381B2 (en) * 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021143767A1 (zh) * 2020-01-15 2021-07-22 信达生物制药(苏州)有限公司 结合pd-1和pd-l1的双特异性抗体的制剂及其用途
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
JP2023116826A (ja) * 2020-05-20 2023-08-23 中外製薬株式会社 抗原結合分子
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
CN114601924A (zh) * 2020-12-09 2022-06-10 信达生物制药(苏州)有限公司 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
WO2011066342A2 (en) * 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012037659A1 (en) 2010-09-24 2012-03-29 Zymeworks Inc. System for molecular packing calculations
CA2812721C (en) 2010-09-30 2019-01-15 Zymeworks Inc. Simplifying residue relationships in protein design
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
EP2681245B1 (en) 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
RU2014148704A (ru) 2012-05-10 2016-07-10 Займворкс Инк. Конструкции одноруких моновалентных антител и их использование
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
CN105121630B (zh) 2012-10-03 2018-09-25 酵活有限公司 定量重链和轻链多肽对的方法
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
KR102264570B1 (ko) 2012-11-28 2021-06-14 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
CN106062206A (zh) 2014-01-15 2016-10-26 酵活有限公司 双特异性cd3和cd19抗原结合构建体
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015265457B2 (en) 2014-05-28 2021-02-18 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
TN2017000554A1 (en) * 2015-07-29 2019-04-12 Novartis Ag Novel combination for use in the treatment of cancer
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
WO2017087547A1 (en) 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof

Also Published As

Publication number Publication date
IL271347B2 (en) 2024-04-01
KR102309950B1 (ko) 2021-10-08
TWI714864B (zh) 2021-01-01
IL271347B1 (en) 2023-12-01
TW201920263A (zh) 2019-06-01
JOP20200003A1 (ar) 2020-01-07
JP2020527136A (ja) 2020-09-03
JOP20200003B1 (ar) 2023-03-28
WO2019014091A1 (en) 2019-01-17
CA3069254C (en) 2023-09-12
BR112020000162A2 (pt) 2020-07-14
CL2020000053A1 (es) 2020-10-30
CN110914306B (zh) 2023-06-02
MX2020000242A (es) 2020-08-10
PE20200297A1 (es) 2020-02-06
UA126032C2 (uk) 2022-08-03
JP6953612B2 (ja) 2021-10-27
ZA201908549B (en) 2021-08-25
CO2019015100A2 (es) 2020-04-24
IL271347A (en) 2020-01-30
US11203640B2 (en) 2021-12-21
AR112603A1 (es) 2019-11-20
KR20200021982A (ko) 2020-03-02
CA3069254A1 (en) 2019-01-17
US20190010232A1 (en) 2019-01-10
CR20190576A (es) 2020-03-03
NZ760683A (en) 2023-02-24
EP3652216A1 (en) 2020-05-20
MY195071A (en) 2023-01-08
MA49563A (fr) 2020-05-20
CN110914306A (zh) 2020-03-24
AU2018301326B2 (en) 2021-05-13
AU2018301326A1 (en) 2019-12-19
PH12020500075A1 (en) 2020-11-09
SG11201911817VA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201890278A1 (ru) Антитела к pd-l1
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
EA202091540A1 (ru) Антитела к lilrb2
MY190324A (en) Anti-pd-1 antibodies and compositions
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA202090204A1 (ru) Анти-cd137 антитела
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201992145A1 (ru) Анти-pd-l1-анти-tim-3 биспецифические антитела
EA201791049A1 (ru) Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
EA201990978A1 (ru) Антитела против pd-1
EA202092262A1 (ru) Антитела против cd137 для комбинации с антителами против pd-1
EA202092265A1 (ru) Антитела против cd137 для комбинации с антителами против pd-l1
MX2017015765A (es) Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.
EA201691907A1 (ru) Комбинированная терапия кураксинами
EA201492019A1 (ru) Способы лечения рака с помощью липопептидов